Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $160000.0.

  • RedHill Biopharma's Other Non-Current Assets fell 7834.91% to $160000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $160000.0, marking a year-over-year decrease of 7834.91%. This contributed to the annual value of $148000.0 for FY2024, which is 8126.58% down from last year.
  • Per RedHill Biopharma's latest filing, its Other Non-Current Assets stood at $160000.0 for Q2 2025, which was down 7834.91% from $148000.0 recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Other Non-Current Assets peaked at $16.2 million during Q4 2021, and registered a low of $148000.0 during Q4 2024.
  • Over the past 5 years, RedHill Biopharma's median Other Non-Current Assets value was $16.0 million (recorded in 2022), while the average stood at $10.8 million.
  • In the last 5 years, RedHill Biopharma's Other Non-Current Assets grew by 6.19% in 2021 and then plummeted by 9506.25% in 2023.
  • Over the past 5 years, RedHill Biopharma's Other Non-Current Assets (Quarter) stood at $16.2 million in 2021, then dropped by 1.05% to $16.0 million in 2022, then tumbled by 95.06% to $790000.0 in 2023, then crashed by 81.27% to $148000.0 in 2024, then grew by 8.11% to $160000.0 in 2025.
  • Its Other Non-Current Assets stands at $160000.0 for Q2 2025, versus $148000.0 for Q4 2024 and $739000.0 for Q2 2024.